All hours indicated are CET
01:00pm
|
Session objectives & Give me 5 – what is new for DCB in 2020
Robert Byrne |
01:10pm
|
Case 1: In-Stent Restenosis
Indication 1 – Step by step instructions & practical tips. Stefano Galli |
01:20pm |
Q&A Session - Robert Byrne
|
1:30pm
|
Case 2: Bifurcation
Indication 2 – Step by step instructions & practical tips. Hee Hwa Ho |
1:40pm |
Q&A Session - Marco Wainstein
|
1:50pm
|
Case 3: Small Vessel Disease
Indication 3 – Step by step instructions & practical tips. John Graham |
2:00pm
|
Q&A Session - Robert Byrne
|
2:10pm |
Session evaluation & Give me 5 - Key learnings/ Practical tips Marco Wainstein |
Daniel W. Congratulation to all speakers. Great Job Marco (good to see you in incathlab). DCB for ISR is a great option. DCB for small native vessels de novo disease has been prooven to be non inferior to DES (BASKET small II). The discussion about paclitaxel eluting DCB and mortality is over now (publication of Bruno Scheller in JACC 1 month ago). Let us see what the sirolimus DCB will do in future trials.